Table 3 Clinical and treatment-related characteristics of study participants (n = 324)
Variables | Frequency (n) | Percent (%) |
|---|---|---|
Total duration since confirmed | ||
< 5 years 5-9 Year > 9 year | 54 59 211 | 16.7 18.2 65.1 |
Baseline CD4 count | ||
< 200 cell/mm3 200–350 cell/mm3 > 350 cell/mm3 | 69 153 102 | 21.3 47.2 31.5 |
CD4 count at initiation | ||
< 200 cell/mm3 200–350 cell/mm3 > 350 cell/mm3 | 66 154 104 | 20.4 47.5 32.1 |
Resent CD4 count | ||
< 200 cell/mm3 200–350 cell/mm3 > 350 cell/mm3 | 4 18 302 | 1.2 5.6 93.2 |
Baseline WHO clinical stage | ||
Stage l Stage ll Stage lll Stage lv | 173 66 71 14 | 53.4 20.4 21.9 4.3 |
WHO clinical stage at ART initiation | ||
Stage I Stage II Stage III Stage IV | 178 65 67 14 | 54.9 20.1 20.7 4.3 |
Recent WHO clinical stage | ||
Stage I Stage II Stage III | 314 6 4 | 96.9 1.9 1.2 |
Opportunistic infection | ||
Yes No | 25 299 | 7.7 92.3 |
Total time of using ART drug | ||
< 10 10–20 > 20 | 172 143 9 | 53.1 44.1 2.8 |
ART regime at initiation | ||
D4t-3TC-NVP (1a) D4T-3TC-EFV (1b) AZT-3TC-NVP (1c) AZT-3TC-EFV(1d) TDF-3TC-EFV (1e) TDF-3TC-NVP (1f) | 37 28 113 66 57 23 | 11.4 8.6 34.9 20.4 17.6 7.1 |
Any art regime change | ||
Yes No | 305 19 | 94.1 5.9 |
Current ART regime you use | ||
First line Second line | 315 9 | 97.2 2.8 |
Use of prophylaxis | ||
Yes No | 218 106 | 67.3 32.7 |
Type of prophylaxis | ||
INH CPT | 134 84 | 41.4 25.9 |